ClinicalTrials.gg
CompletedNCT00705367Updated Jul 30, 2013Results posted

Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg

A Phase 1 interventional study of Placebo and Abatacept in Lupus Nephritis, sponsored by Bristol-Myers Squibb. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-30.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 96 studies in Lupus Nephritis with a site in China — 43 open to participants now, 46 under way, 8 of them phase 3. Lupus Nephritis · China.

Enrollment
80th of 88
13 · median 51
Started
2008
with 1 other
Phase 1
15 of 96
11 open now
Registered
11th of 96
by date
Lead sponsor
3 of 96
Bristol-Myers Squibb

Among the 96 studies in Lupus Nephritis with a site in China, this one is the 80th largest by enrollment of the 88 interventional ones that give a count, is one of 2 that started in 2008, is one of 15 in phase 1, and was the 11th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 136 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

43 of the 96 studies in Lupus Nephritis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Lupus Nephritis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus (SLE)

03

Conditions studied

  • Lupus Nephritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, at least 18 years of age, with a diagnosis of systemic lupus erythematosus (SLE) and with lupus nephritis currently stable for the last 3 months without change in treatment for lupus nephritis
  • Stable renal disease
  • No flaring of other organ systems in a minimum of the last 3 months

Exclusion criteria

Exclusion Criteria:

  • Unstable lupus nephritis and serum creatinine >3 mg/dL
  • Progressive renal failure, end stage renal disease, or renal transplant requiring continuous dialysis
  • Severe unstable, , or progressive SLE
  • History of cancer
  • Participants at risk for tuberculosis
  • disease other than SLE as main diagnosis
  • or herpes zoster infection
  • Hepatitis-B surface antigen-positive or antibody-positive participants
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
13 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Abatacept, 30 mg/kg

    Drug: Abatacept

  • Other
    Abatacept, 10 mg/kg

    Open-label long-term extension phase

    Drug: Abatacept

Interventions

  • DrugPlacebo

    Infusion, Intravenous, single dose, Day 1

  • Infusion, Intravenous, 30mg/kg, single dose, Day 1

    Also known as: Orencia, BMS-188667

  • Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study

    Also known as: Orencia, BMS-188667

06

What researchers measure

Primary outcomes

  1. Short-term Period: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, Discontinuations and Infusional AEs

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.

    Time frame: From Day 1 of double-blind period to 1st dose of long-term period

  2. Short-term Period: Number of Adverse Events (AEs) Related to Study Drug

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. Intensity = mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening/disabling (grade 4).

    Time frame: From Day 1 of double-blind period to 1st dose of long-term period

  3. Short-term Period: MeanSystolic and Diastolic Blood Pressure

    Vital sign measurements are summarized without regard to position (sitting, standing, supine).

    Time frame: Day 1 predose and postdose and Day 2

  4. Short-term Period: Mean Heart Rate

    Vital signs measurements are summarized without regard to position (sitting, standing, supine).

    Time frame: Day 1 predose and postdose and Day 2

  5. Short-term Period: Mean Respirations Rate

    Vital sign measurements are summarized without regard to position (sitting, standing, supine).

    Time frame: Day 1 predose and postdose and Day 2

  6. Short-term Period: Mean Temperature

    Vital sign measurements are summarized without regard to position (sitting, standing, supine).

    Time frame: Day 1 predose and postdose and Day 2

  7. Short-term Period: Number of Participants With Clinical Laboratory and Electrocardiogram (ECG) Abnormalities

    Laboratory tests consisted of complete blood count, chemistry, and urinalysis.

    Time frame: Screening and Days 1 and 2

Secondary outcomes

  1. Long-term Period: Number of Participants With Death as Outcome, Serious AEs (SAEs), Discontinuations Due to AEs, and Treatment-related AEs

    AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.

    Time frame: Days 15 to 56 days post last dose of the long-term period

  2. Minimum (Cmin) Plasma Concentration of Abatacept

    Cmin is the minimum, or trough, concentration of a drug observed after its administration and just prior to the administration of a subsequent dose.

    Time frame: Days 15, 29, 85, 169, 253 and 337

  3. Maximum (Cmax) Plasma Concentration of Abatacept

    Cmax is a drug's maximum, or peak, concentration observed after its administration.

    Time frame: Postdosing Day 1

  4. Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests

    preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. hemoglobin (g/dL): \>3g/dL drop from preRX; hematocrit (%): \<0.75\*preRX; erythrocytes (\*10\^6 c/uL): \<0.75\*preRX; platelet count (\*10\^9 c/L): \<0.67\*LLN or \>1.5\*ULN, or \<100,000/mm\^3 or if preRX\<LLN, use \<0.5\*preRX and \<100,000/mm\^3; leukocytes (\*10\^3 c/uL): \<0.75\*LLN, \>1.25\*ULN, \<0.8\*preRX if preRX \<LLN or \>1.2\*preRX if preRX \>ULN; \>ULN if preRX \<LLN, \<LLN if \>ULN preRX; neutrophils+bands (\*10\^3 c/uL): if value \<1.00\*10\^3 c/uL; lymphocytes (\*10\^3 c/uL): if value \<0.750\*10\^3 c/uL or if value \>7.50\*10\^3 c/uL; monocytes (\*10\^3 c/uL): if value \>2000/mm\^3; basophils (\*10\^3 c/uL): if value \>400/mm\^3; eosinophils (\*10\^3 c/uL): if value\> 0.750\*10\^3 c/uL

    Time frame: Days 15 to 56 days post last dose of the long-term period

  5. Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)

    preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Glucose (mg/dL): \<65 or \>220. Glucose, fasting(mg/dL): \<0.8\*LLN or \>1.5\* ULN; if preRX\<LLN, use \<0.8\*preRX or \>ULN; if preRX\>ULN, use \>2.0\*preRX or \<LLN. Protein, total (g/dL): \<0.9\*LLN or \>1.1\*ULN; if preRX\<LLN, use 0.9\*preRX or \>ULN if preRX \>ULN, use 1.1\*preRX or \<LLN. Albumin (g/dL): \<0.9\*LLN, or if preRX\<LLN use \<0.75\*preRX. Uric acid (mg/dL): \>1.5\*ULN; if preRX\>ULN use \>2\*preRX. Protein, urine: if missing preRX, use\>=2; if \>=4; if preRX=0 or 0.5, use \>=2; if preRX=1, use \>=3, or if preRX=2 or 3, use \>= 4. Glucose, urine: if preRX missing, use \>=2; if \>=4, or if preRX=0 or 0.5 use \>=2,or if preRX=1, use \>=3, or if preRX=2 or 3 use \>=4. Blood, urine: if preRX missing, use\>= 2, or if \>=4, or if preRX=0 or 0.5, use \>=2, or if preRX=1, use \>=3; if preRX=2 or 3 use \>=4. WBC, urine (hpf): if missing preRX, use\>= 2, or if \>= 4, or if preRX =0 or 0.5 use \>=2, or if preRX=1 use \>=3, or if preRX=2 or 3 use \>=4.

    Time frame: Days 15 to 56 days post last dose of the long-term period

  6. Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)

    ULN=upper limit of normal; preRX=pretreatment: ALP (U/L): \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; AST (U/L): \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALT (U/L): \>3X\*ULN, or if preRX\>ULN, use \>4\*preRX; GGT (/L): \>\*ULN, or if preRX\>ULN, use \>3\*preRX; bilirubin (mg/dL): \>2\*ULN, or if preRX\>ULN, use \>4\*preRX; BUN (mg/dL):\>2\*preRX; sodium: \<.95\*LLN, \>1.05\*ULN, \<.95\* preRX if \<LLN preRX, \>1.05\*preRX if \>ULN preRX; \>ULN if \<LLN preRX, \<LLN if \>ULN preRX; potassium: chloride: calcium: phosphorous:

    Time frame: Days 15 to 56 days post last dose of the long-term period

  7. Long-term Period: Number of Participants With Abatacept-specific Antibodies

    Antiabatacept antibodies in human serum were assayed using a validated electrochemiluminescent immunoassay during the period of known analyte stability.

    Time frame: Day15 to 56 days post last dose of the long-term period

07

Results

Posted Jun 3, 2010

Participant flow

Short-term Period
Participant flow — Short-term Period
MilestoneAbatacept, 30/10 mg/kgPlacebo/Abatacept,10 mg/kg
Started63
Completed63
Not completed00
Long-term Extension Period
Participant flow — Long-term Extension Period
MilestoneAbatacept, 30/10 mg/kgPlacebo/Abatacept,10 mg/kg
Started90
Completed00
Not completed90
Withdrew: Adverse event20
Withdrew: Withdrawal by subject20
Withdrew: Lack of efficacy10
Withdrew: No longer met study criteria10
Withdrew: Administrative reason by sponsor30

Outcome measures

PrimaryShort-term Period: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, Discontinuations and Infusional AEs

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.

Time frame:
From Day 1 of double-blind period to 1st dose of long-term period
Reported as:
Number · Participants
Short-term Period: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, Discontinuations and Infusional AEs
ParticipantsAbatacept (30 mg/kg)Placebo
Deaths00
SAEs00
AEs31
Discontinued due to AEs00
Acute infusional AEs00
Peri-infusional AEs00
SecondaryLong-term Period: Number of Participants With Death as Outcome, Serious AEs (SAEs), Discontinuations Due to AEs, and Treatment-related AEs

AE=any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in the development of drug dependency or drug abuse, is an important medical event.

Time frame:
Days 15 to 56 days post last dose of the long-term period
Reported as:
Number · Participants
Long-term Period: Number of Participants With Death as Outcome, Serious AEs (SAEs), Discontinuations Due to AEs, and Treatment-related AEs
ParticipantsAbatacept (10 mg/kg)
Deaths0
SAEs0
Discontinuations due to AEs2
AEs8
Treatment-related AEs6
SecondaryMinimum (Cmin) Plasma Concentration of Abatacept

Cmin is the minimum, or trough, concentration of a drug observed after its administration and just prior to the administration of a subsequent dose.

Time frame:
Days 15, 29, 85, 169, 253 and 337
Reported as:
Mean · ug/mL
Minimum (Cmin) Plasma Concentration of Abatacept
ug/mLAbatacept (10 mg/kg)
Day 15 (n=6)55.47 ± 29.356
Day 29 (N=9)42.69 ± 12.534
Day 85 (n=8)18.54 ± 11.492
Day 169 (n=7)22.66 ± 10.312
Day 253 (n=7)28.24 ± 13.883
Day 337 (n=4)25.98 ± 6.833
PrimaryShort-term Period: Number of Adverse Events (AEs) Related to Study Drug

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. Intensity = mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening/disabling (grade 4).

Time frame:
From Day 1 of double-blind period to 1st dose of long-term period
Reported as:
Number · Events
Short-term Period: Number of Adverse Events (AEs) Related to Study Drug
EventsAbatacept (30 mg/kg)Placebo
Dizziness (mild)10
Oropharyngeal pain (mild)10
Diarrhea (mild)01
PrimaryShort-term Period: MeanSystolic and Diastolic Blood Pressure

Vital sign measurements are summarized without regard to position (sitting, standing, supine).

Time frame:
Day 1 predose and postdose and Day 2
Reported as:
Mean · mm Hg
Short-term Period: MeanSystolic and Diastolic Blood Pressure
mm HgAbatacept (30 mg/kg)Placebo
Systolic blood pressure: Day 1 predose129.0 ± 20.47133.0 ± 8.89
Systolic blood pressure: Day 1 postdose125.8 ± 19.58131.7 ± 9.29
Diastolic blood pressure: Day 1 predose84.2 ± 8.8678.3 ± 12.06
Diastolic blood pressure: Day 1 postdose82.7 ± 9.5882.7 ± 14.22
Systolic blood pressure: Day 2127.5 ± 13.69126.7 ± 11.55
Diastolic blood pressure: Day 279.5 ± 8.6978.3 ± 10.41
PrimaryShort-term Period: Mean Heart Rate

Vital signs measurements are summarized without regard to position (sitting, standing, supine).

Time frame:
Day 1 predose and postdose and Day 2
Reported as:
Mean · beats per minute
Short-term Period: Mean Heart Rate
beats per minuteAbatacept (30 mg/kg)Placebo
Day 1 predose77.0 ± 8.4981.0 ± 10.15
Day 1 postdose81.2 ± 4.8387.7 ± 19.60
Day 283.5 ± 4.4684.0 ± 5.29
PrimaryShort-term Period: Mean Respirations Rate

Vital sign measurements are summarized without regard to position (sitting, standing, supine).

Time frame:
Day 1 predose and postdose and Day 2
Reported as:
Mean · Respirations per minute
Short-term Period: Mean Respirations Rate
Respirations per minuteAbatacept (30 mg/kg)Placebo
Day 1 predose17.7 ± 2.0719.7 ± 2.08
Day 1 postdose18.7 ± 1.6320.3 ± 2.52
Day 214.0 ± 3.3517.3 ± 1.15
SecondaryMaximum (Cmax) Plasma Concentration of Abatacept

Cmax is a drug's maximum, or peak, concentration observed after its administration.

Time frame:
Postdosing Day 1
Reported as:
Geometric mean · ug/mL
Maximum (Cmax) Plasma Concentration of Abatacept
ug/mLAbatacept (10 mg/kg)
Maximum (Cmax) Plasma Concentration of Abatacept463.10 ± 17
PrimaryShort-term Period: Mean Temperature

Vital sign measurements are summarized without regard to position (sitting, standing, supine).

Time frame:
Day 1 predose and postdose and Day 2
Reported as:
Mean · Degrees Celsius
Short-term Period: Mean Temperature
Degrees CelsiusAbatacept (30 mg/kg)Placebo
Day 1 predose36.7 ± 0.5136.7 ± 0.15
Day 1 postdose36.8 ± 0.5936.9 ± 0.26
Day 236.9 ± 0.1136.9 ± 0.12
PrimaryShort-term Period: Number of Participants With Clinical Laboratory and Electrocardiogram (ECG) Abnormalities

Laboratory tests consisted of complete blood count, chemistry, and urinalysis.

Time frame:
Screening and Days 1 and 2
Reported as:
Number · Participants
Short-term Period: Number of Participants With Clinical Laboratory and Electrocardiogram (ECG) Abnormalities
ParticipantsAbatacept (30 mg/kg)Placebo
Laboratory Abnormalities00
ECG Abnormalities00
SecondaryLong-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests

preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. hemoglobin (g/dL): \>3g/dL drop from preRX; hematocrit (%): \<0.75\*preRX; erythrocytes (\*10\^6 c/uL): \<0.75\*preRX; platelet count (\*10\^9 c/L): \<0.67\*LLN or \>1.5\*ULN, or \<100,000/mm\^3 or if preRX\<LLN, use \<0.5\*preRX and \<100,000/mm\^3; leukocytes (\*10\^3 c/uL): \<0.75\*LLN, \>1.25\*ULN, \<0.8\*preRX if preRX \<LLN or \>1.2\*preRX if preRX \>ULN; \>ULN if preRX \<LLN, \<LLN if \>ULN preRX; neutrophils+bands (\*10\^3 c/uL): if value \<1.00\*10\^3 c/uL; lymphocytes (\*10\^3 c/uL): if value \<0.750\*10\^3 c/uL or if value \>7.50\*10\^3 c/uL; monocytes (\*10\^3 c/uL): if value \>2000/mm\^3; basophils (\*10\^3 c/uL): if value \>400/mm\^3; eosinophils (\*10\^3 c/uL): if value\> 0.750\*10\^3 c/uL

Time frame:
Days 15 to 56 days post last dose of the long-term period
Reported as:
Number · Participants
Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests
ParticipantsAbatacept, 30/10 mg/kg
Hemoglobin (low)1
Hemoglobin (high)NA
Hematocrit (low)1
Hematocrit (high)NA
Erythrocytes (low)0
Erythrocytes (high)NA
Platelet count (low or high)0
Leukocytes (low)1
Leukocytes (high)0
Neutrophils +bands (absolute) (low)NA
Neutrophils +bands (absolute) (high)0
Absolute lymphocytes (low)6
Absolute lymphocytes (high)0
Absolute monocytes (low)NA
Absolute monocytes (high)0
Absolute basophils (low)NA
Absolute basophils (high)0
Absolute eosinophils (low)NA
Absolute eosinophils (high)0
SecondaryLong-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)

preRX=pretreatment; LLN=lower limit of normal; ULN=upper limit of normal. Glucose (mg/dL): \<65 or \>220. Glucose, fasting(mg/dL): \<0.8\*LLN or \>1.5\* ULN; if preRX\<LLN, use \<0.8\*preRX or \>ULN; if preRX\>ULN, use \>2.0\*preRX or \<LLN. Protein, total (g/dL): \<0.9\*LLN or \>1.1\*ULN; if preRX\<LLN, use 0.9\*preRX or \>ULN if preRX \>ULN, use 1.1\*preRX or \<LLN. Albumin (g/dL): \<0.9\*LLN, or if preRX\<LLN use \<0.75\*preRX. Uric acid (mg/dL): \>1.5\*ULN; if preRX\>ULN use \>2\*preRX. Protein, urine: if missing preRX, use\>=2; if \>=4; if preRX=0 or 0.5, use \>=2; if preRX=1, use \>=3, or if preRX=2 or 3, use \>= 4. Glucose, urine: if preRX missing, use \>=2; if \>=4, or if preRX=0 or 0.5 use \>=2,or if preRX=1, use \>=3, or if preRX=2 or 3 use \>=4. Blood, urine: if preRX missing, use\>= 2, or if \>=4, or if preRX=0 or 0.5, use \>=2, or if preRX=1, use \>=3; if preRX=2 or 3 use \>=4. WBC, urine (hpf): if missing preRX, use\>= 2, or if \>= 4, or if preRX =0 or 0.5 use \>=2, or if preRX=1 use \>=3, or if preRX=2 or 3 use \>=4.

Time frame:
Days 15 to 56 days post last dose of the long-term period
Reported as:
Number · Participants
Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)
ParticipantsAbatacept, 30/10 mg/kg
Glucose, serum (low)2
Glucose, serum (high)0
Glucose, fasting serum (low)0
Glucose, fasting serum (high)0
Protein, total (low)0
Protein, total (high)0
Albumin (low)0
Albumin (high)NA
Uric acid (low)NA
Uric acid (high)0
Protein, urine (low)NA
Protein, urine (high)1
Glucose, urine (low)NA
Glucose, urine (high)0
Blood, urine (low)NA
Blood, urine (high)5
WBC, urine (low)NA
White blood cell (WBC) count, urine (high)3
SecondaryLong-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)

ULN=upper limit of normal; preRX=pretreatment: ALP (U/L): \>2\*ULN, or if preRX\>ULN, use \>3\*preRX; AST (U/L): \>3\*ULN, or if preRX\>ULN, use \>4\*preRX; ALT (U/L): \>3X\*ULN, or if preRX\>ULN, use \>4\*preRX; GGT (/L): \>\*ULN, or if preRX\>ULN, use \>3\*preRX; bilirubin (mg/dL): \>2\*ULN, or if preRX\>ULN, use \>4\*preRX; BUN (mg/dL):\>2\*preRX; sodium: \<.95\*LLN, \>1.05\*ULN, \<.95\* preRX if \<LLN preRX, \>1.05\*preRX if \>ULN preRX; \>ULN if \<LLN preRX, \<LLN if \>ULN preRX; potassium: chloride: calcium: phosphorous:

Time frame:
Days 15 to 56 days post last dose of the long-term period
Reported as:
Number · Participants
Long-term Period: Number of Participants With Marked Abnormalities in Results of Clinical Laboratory Tests (Continued)
ParticipantsAbatacept, 30/10 mg/kg
Alkaline phosphatase (ALP) (low)NA
ALP (high)0
Aspartate aminotransferase (AST) (low)NA
AST (high)0
Alanine aminotransferase (ALT) (low)NA
ALT (high)0
G-glutamyl transferase (GGT) (low)NA
GGT (high)0
Bilirubin, total (low)NA
Bilirubin, total (high)0
Blood urea nitrogen (BUN) (low)NA
BUN (high)0
Sodium, serum (low)0
Sodium, serum (high)1
Potassium, serum (low)0
Potassium, serum (high)0
Chloride, serum (low)0
Chloride, serum (high)0
Calcium, total (low)0
Calcium, total (high)0
Phosphorus, inorganic (low)0
Phosphorus, inorganic (high)2
SecondaryLong-term Period: Number of Participants With Abatacept-specific Antibodies

Antiabatacept antibodies in human serum were assayed using a validated electrochemiluminescent immunoassay during the period of known analyte stability.

Time frame:
Day15 to 56 days post last dose of the long-term period
Reported as:
Number · Participants
Long-term Period: Number of Participants With Abatacept-specific Antibodies
ParticipantsAbatacept (10 mg/kg)
Long-term Period: Number of Participants With Abatacept-specific Antibodies0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept 30 mg/kg—0/6 (0%)3/6 (50%)
Placebo—0/3 (0%)1/3 (33.3%)
Most frequent other events
Most frequent other events
EventAbatacept 30 mg/kgPlacebo
DIARRHOEAGastrointestinal disorders1/61/3
DIZZINESSNervous system disorders1/60/3
VOMITINGGastrointestinal disorders1/60/3
ABDOMINAL PAINGastrointestinal disorders1/60/3
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders1/60/3

Baseline characteristics

Age Continuous
Age Continuous(years)Abatacept (30 mg/kg)PlaceboTotal
Mean32.50 ± 8.7641.33 ± 8.3335.44 ± 9.21
Sex: Female, Male
Sex: Female, Male(Participants)Abatacept (30 mg/kg)PlaceboTotal
Female628
Male011
Region of Enrollment
Region of Enrollment(participants)Abatacept (30 mg/kg)PlaceboTotal
China639
Duration of Lupus Nephritis
Duration of Lupus Nephritis(months)Abatacept (30 mg/kg)PlaceboTotal
Mean41.23 ± 32.9085.26 ± 65.0355.90 ± 47.10
Duration of Systemic Lupus Erythematosus (SLE)
Duration of Systemic Lupus Erythematosus (SLE)(years)Abatacept (30 mg/kg)PlaceboTotal
Mean7.20 ± 5.0611.11 ± 3.188.50 ± 4.73
Weight
Weight(kg)Abatacept (30 mg/kg)PlaceboTotal
Mean58.83 ± 10.3863.67 ± 4.0460.44 ± 8.79
08

Study locations

1 site
  • Local Institution
    Shanghai, Shanghai 200001, China
09

References and documents

Publications

  • Liu MF, Wang CR, Lin LC, Wu CR. CTLA-4 gene polymorphism in promoter and exon-1 regions in Chinese patients with systemic lupus erythematosus. Lupus. 2001;10(9):647-9. doi: 10.1191/096120301682430249. PubMed 11678454 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Jan 2009 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2008
First posted
Jun 26, 2008
Start
Aug 2008
Primary completionActual
Jan 2009
CompletionActual
Jul 2011
Results first posted
Jun 3, 2010
Last update
Jul 30, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00705367
Responsible party
Sponsor
First posted
Jun 26, 2008
Start date
Aug 2008
Primary completion
Jan 2009
Completion
Jul 2011
Results posted
Jun 3, 2010
Last update
Jul 30, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion